Antibody Information
General Information of This Antibody
| Antibody ID | ANI0QYT006 |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Sonesitatug |
|||||
| Antigen Name | Claudin-18.2 (CLDN18.2) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
QVQLQESGPGLVKPSETLSLTCTVSGGSISSNYAWNWIRQPPGKGLEWIGYIYYSGNTNY
NPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATSYYGNSFIYWGQGTLVTVSS Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTR
ESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNAYSFPWTFGQGTKVEIK Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
CMG-901 [Phase 3]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
75.00% (Gastric/GEJ Cancer)
|
|||
| Patients Enrolled |
Patients with advanced malignant tumors.
|
||||
| Administration Dosage |
Day 1 in 3-week (Q3W) cycle 3.40 mg/kg.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04805307 | Clinical Status | Phase 1 | ||
| Clinical Description |
An open-label, phase 1, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and antitumor activities of CMG901 in subjects with advanced unresectable or metastatic solid tumor.
|
||||
References